Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.68 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.68 |
| ▸ | PGR | P06401 | 2/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5124515 | 1.00 | ESR1 (0.68) | ESR1ESR2PGRCYP19A1PTGS2 | |
| SCHEMBL5124519 | 1.00 | ESR1 (0.68) | ESR1ESR2PGRCYP19A1PTGS2 | |
| SCHEMBL5069462 | 0.94 | ESR1 (0.76) | ESR1ESR2PGRCYP19A1PTGS2 | |
| SCHEMBL5069452 | 0.94 | ESR1 (0.76) | ESR1ESR2PGRCYP19A1PTGS2 | |
| SCHEMBL5069457 | 0.94 | ESR1 (0.76) | ESR1ESR2PGRCYP19A1PTGS2 | |
| SCHEMBL6672982 | 0.92 | ESR1 (0.59) | ESR1ESR2PGRCYP19A1PTGS2 | |
| SCHEMBL6672979 | 0.92 | ESR1 (0.59) | ESR1ESR2PGRCYP19A1PTGS2 | |
| SCHEMBL6672984 | 0.92 | ESR1 (0.59) | ESR1ESR2PGRCYP19A1PTGS2 | |
| SCHEMBL5069489 | 0.90 | PTGS2 (0.66) | ESR1ESR2PGRCYP19A1PTGS2 | |
| SCHEMBL5069485 | 0.90 | PTGS2 (0.66) | ESR1ESR2PGRCYP19A1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323587-B2 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323587-B2 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323587-B2 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-7045540-B2 | Selective estrogen receptor modulators | BRISTOL MEYERS SQUIBB COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| US-20050267183-A1 | Selective estrogen receptor modulators | KALTENBACH ROBERT F | 2005-12-01 | — | — | US | disclosed |
| US-20050245602-A1 | Selective estrogen receptor modulators | KALTENBACH ROBERT F | 2005-11-03 | — | — | US | disclosed |
| US-6927224-B2 | Selective estrogen receptor modulators | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-09 | — | — | US | disclosed |
| US-20030105148-A1 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-05 | — | — | US | disclosed |
| US-20030073671-A1 | Non-steroidal ligands for the estrogen receptor | WILLSON TIMOTHY MARK (US) | 2003-04-17 | — | — | US | disclosed |
| US-20010053774-A1 | Non-steroidal ligands for the estrogen receptor | GLAXO WELLCOME INC.. | 2001-12-20 | — | — | US | disclosed |
| US-6207716-B1 | FOR PROPHYLAXIS AND THERAPY OF OSTEOPOROSIS, ARTHRITIS, BREAST CANCER, CARDIOVASCULAR DISEASE | GLAXO WELLCOME INC. | 2001-03-27 | — | — | US | disclosed |
| US-5877219-A | Non-steroidal ligands for the estrogen receptor | GLAXO WELLCOMEINC. (US) | 1999-03-02 | — | — | US | disclosed |
| WO-1999007668-A1 | NON-STEROIDAL LIGANDS FOR THE ESTROGEN RECEPTOR | GLAXO WELLCOME INC. (US) | 1999-02-18 | — | — | WO | disclosed |
| US-5681835-A | USEFUL FOR TREATING OSTEOPOROSIS | GLAXO WELLCOME INC. (US) | 1997-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245602-A1 | Selective estrogen receptor modulators | ESR1, ESR2, GPER1 | ESR1 1/4885ESR2 2/4885PGR 13/4885 |
| US-20030105148-A1 | Selective estrogen receptor modulators | ESR1, GPER1, PTGIR | ESR1 1/4885ESR2 8/4885PGR 9/4885 |
| US-20010053774-A1 | Non-steroidal ligands for the estrogen receptor | ESRRB, ESR2, ESRRA | ESR1 6/4885ESR2 2/4885PGR 12/4885 |
| US-20030073671-A1 | Non-steroidal ligands for the estrogen receptor | ESRRB, ESR2, ESRRA | ESR1 6/4885ESR2 2/4885PGR 12/4885 |
| US-20050267183-A1 | Selective estrogen receptor modulators | ESR2, ESR1, GPER1 | ESR1 2/4885ESR2 1/4885PGR 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.